Hasil Pencarian  ::  Simpan CSV :: Kembali

Abstrak :
Kanker telah diketahui sebagai faktor risiko kuat penyebab tromboemboli, baik emboli paru maupun trombosis vena dalam. Emboli paru sendiri seringkali tidak bergejala padahal angka mortalitas bisa mencapai 80%. Tipe histopatologi adenokarsinoma merupakan salah satu faktor risiko yang meningkatkan kejadian emboli paru. Penelitian ini bertujuan untuk mengetahui proporsi kejadian emboli paru dan trombosis vena pada kelompok kemungkinan tinggi menurut skor Revisi Geneva dan memperoleh besar kemungkinan kejadian emboli paru (EP) serta hubungannya dengan tipe histopatologi kanker padat. Penelitian menggunakan potong lintang dan didapatkan 124 subjek diikutkan dalam penelitian ini yang terdiri atas kelompok adenokarsinoma dan non adenokarsinoma masing-masing sebesar 62 subjek. Berdasarkan skor Revisi Geneva, sebanyak 11 (8,8%) subjek termasuk ke dalam kelompok kemungkinan rendah, 96 (77,4%) subjek termasuk ke dalam kelompok kemungkinan menengah dan 17 (13,8%) subjek ke dalam kelompok kemungkinan tinggi. Kejadian tromboemboli vena pada kelompok kemungkinan tinggi mencapai 94,1% dengan 58,8% mengalami emboli paru dan trombosis vena dalam secara bersamaan, 11,8% hanya mengalami emboli paru saja dan 23,6% mengalami thrombosis vena dalam saja. Tipe histopatologi adenokarsinoma memiliki risiko 2,58 kali lebih tinggi untuk masuk kedalam kelompok kemungkinan kejadian tinggi emboli paru menurut skor Revisi Geneva bila dibandingkan pada subjek dengan tipe histopatologi non adenokarsinoma. Sebagai kesimpulan, kanker padat dengan tipe histopatologi adenokarsinoma meningkatkan kemungkinan kejadian emboli paru bila dibandingkan dengan tipe non adenokarsinoma.

---

Cancer is widely known as a strong risk factor of thromboembolism, which consist of two kind are pulmonary embolism and deep vein thrombosis. We mainly focused on pulmonary embolism in this research. Pulmonary embolism is often asymptomatic which the mortality rate can reach 80%. Adenocarcinoma histopathological type has been proved as one of the risk factors that increase the occurance of pulmonary embolism. This research determine the proportion of pulmonary embolism and deep vein thrombosis events in high clinical probability group based on Revised Geneva score and the correlation with solid tumor histopathological type. This research used cross sectional method with 124 subjects participated in this research which consisted of 62 patients for each of adenocarcinoma and non-adeocarcinoma group. Mean of patient age was 52 years old and the sum of female participant was larger than male. Based on Revised Geneva score, 11 (8,8%) participants were in low risk clinical probability group, 96 (77,4%) participant were in middle risk clinical probability group and the rest of 17 (13,8%) participants were in high risk clinical probability group. The total event of vena thromboembolism in high risk clinical probability group reached 94,1% whereas 58,8% got both pulmonary embolism and deep vein thrombosis simultaneously, 11,8% with pulmonary embolism alone and 23,6% with vein deep vein thrombosis alone. Subjects with histopathological type of AC were 2.58 times greater to be a high-probability group of the Revised Geneva Score compared with NAC. As the conclusion, Solid cancer with histopathological type of AC increases the likelihood of PE incidence when compared with NAC.

Abstrak :
ABSTRAK
Latar Belakang: Antikoagulan warfarin dipakai seumur hidup pada pasien pascabedah katup jantung mekanik karena memiliki risiko tromboemboli. Dosis warfarin berlebih nilai international normalized ratio/INR di atas rentang target optimum menimbulkan efek samping perdarahan, sedangkan dosis warfarin kurang nilai INR di bawah rentang target optimum menimbulkan tromboemboli. Nilai INR optimum berbagai ras dan suku berbeda-beda. Di RS JPDHK belum pernah dilakukan studi mengenai penggunaan warfarin dan target INR optimum, padahal jumlah pasien pascabedah katup jantung mekanik semakin meningkat dari 411 pasien pada tahun 2011 menjadi 685 pasien pada tahun 2016. Penelitian ini dilakukan untuk mengetahui frekuensi efek samping perdarahan dan tromboemboli pada pasien tersebut, nilai INR optimum dan kemungkinan adanya interaksi warfarin dengan obat lain.Metode: Penelitian ini merupakan penelitian retrospektif yang diambil dari rekam medik RS JPDHK. Data frekuensi perdarahan dan tromboemboli diambil dari semua pasien yang mendapatkan terapi warfarin pascabedah katup jantung mekanik tahun 2011. Nilai INR, dosis warfarin dan kemungkinan interaksi warfarin dievaluasi pada 30 pasien perdarahan, 30 pasien tromboemboli dan 30 pasien yang tidak mengalami komplikasi melalui data rekam medik pasien bedah katup jantung mekanik sebelum tahun 2017.Hasil: Jumlah pasien yang menjalani bedah katup jantung mekanik tahun 2011 adalah 43 dan didapatkan frekuensi perdarahan mayor 11 pasien 25,6 , perdarahan minor 5 pasien 11,6 serta tromboemboli 10 pasien 23,3 . Terdapat perbedaan bermakna p.

---

ABSTRACT
Background Anticoagulant warfarin is used for a lifetime in patients after mechanical valve replacement procedure because of tromboembolic risks. Warfarin should be used carefully since it has a narrow therapeutic window. Warfarin overdose INR above the target range is associated with bleeding, while underdose INR below the target range may lead to among thromboembolic complications. The optimum INR value may be different races and ethnicity. The INR value recomended by the American Heart Association AHA American College of Cardiology ACC 2017 is 2.5 3.0. In National Cardiac Center ldquo Harapan Kita rdquo Hospital no study has been carried out on the use of warfarin and the optimum INR value. Mean while, the number of patients with prosthetic mechanical valves is increasing from 450 patients in 2011 to 685 patients in 2016. This study aimed to find out the frequency of bleeding and thromboembolic complications in these patients, the optimum INR value and the possibility of interaction between warfarin and other drugs. Method In this retrospective study, the data of frequency of bleeding and thromboembolic was obtained from the medical records of patients given warfarin after mechanical heart valve replacement in 2011. The data of INR value, warfarin dose, and the possibility of interaction between warfarin and other drugs used concomittantly were evaluated in 30 patients with bleeding, 30 patients with thromboembolic and 30 patients without complication, who had mechanical heart valve replacement procedure prior to 2017.Results Out of 43 patients with mechanical heart valve replacement in 2011, the frequency of major bleeding was 11 patients 25,6 , minor bleeding was 5 patients 11,6 , and thromboembolic was 10 patients 23,3 . The INR mean level in bleeding patients group 6,32, CI95 5.2 7.7 was significantly different p

Abstrak :
Trombo-emboli vena (TEV) umum dijumpai pada pasien rawat inap dan dipertimbangkan sebagai suatu komplikasi tidak hanya bagi pasien post bedah tetapi juga pada pasien dengan kondisi medis lainnya. Kebanyakan pasien rawat inap yang mengalami TEV ataupun emboli paru tidak menjalani prosedur bedah sebelumnya. Beberapa studi besar acak, tersamar ganda dan dengan plasebo seperti MEDENOX, PREVENT dan ARTEMIS telah memastikan manfaat dan keamanan dari tromboprofilaksis terhadap TEV terhadap pasien rawat inap dengan kondisi medis akut. Panduan tahun 2008 dari The American College of Chest Physicians (ACCP) merekomendasikan penilaian risiko bagi setiap pasien dengan kondisi medis tertentu pada saat masuk rumah sakit dan profilaksis VTE, baik dengan regimen antikoagulan ataupun pencegahan secara mekanik, sebaiknya diterapkan bagi mereka yang tergolong berisiko tinggi. Studi-studi lainnya menunjukkan bahwa banyak kasus VTE pada pasien medis terjadi setelah keluar dari perawatan rumah sakit, namun hingga kini belum ada publikasi perihal uji klinis maupun rekomendasi untuk mengevaluasi profilaksis VTE bagi pasien medis rawat jalan. Pada artikel ini, kami mencoba mengulas beberapa literatur untuk kepentingan penilaian risiko dan profilaksis VTE bagi pasien medis rawat inap.

---

Abstract
Venous thromboembolism (VTE) is commonly found in hospitalized patients, considered as complication not only in surgical patients but also in medical patients. The vast majority of hospitalized patients with VTE or pulmonary embolism have not undergone any recent surgery. Several large randomized, double-blind, placebo controlled trials including MEDENOX, PREVENT and ARTEMIS have confirmed the efficacy and safety of VTE thromboprophylaxis for acutely ill medical inpatients. The American College of Chest Physicians (ACCP) Guidelines 2008 recommend a risk assessment at the time hospital admission for every medical patients and VTE prophylaxis using either anticoagulant medications or mechanical prevention should be applied for those who have high risk condition. Other studies showed that many cases of VTE in medical patients occur after hospital discharge, but still no clinical trials and current recommendation evaluating VTE prophylaxis for medical outpatients have been published yet. In this article, we attempt to review the literatures on importance of risk assessment and VTE prophylaxis for hospitalized medical patients.

Abstrak :
ABSTRACT
Chronic thromboembolic pulmonary hypertension (CTEPH) is currently underdiagnosis and consequently undertreatment in the clinical practice. A deficient in diagnostic modality and treatment availability especially in developing countries makes the CTEPH diagnosis unlikely to confirm. However, high index of clinical suspicion of CTEPH will lead to proper diagnosis and correct treatment with significant reduction in morbidity and mortality. Left untreated, the mean survival time is 6.8 years and the three year mortality rate may be as high as 90%. The pathophysiology, diagnosis and treatment of CTEPH are necessary to be shared among internists and primary care physicians, in order to improve the overall outcome of the patients.